The Impact on Anti-Mullerian Hormone (AMH), uterine fibroid size and uterine artery patency following Uterine Fibroid Embolization (UFE) with a resorbable embolic agent
The Impact on Anti-Mullerian Hormone (AMH), uterine fibroid size and uterine artery patency following Uterine Fibroid Embolization (UFE) with a resorbable embolic agent
The effect of Uterine Fibroid Embolization on fertility and ovarian reserve remains uncertain. We assessed the impact of a new resorbable, spherical particle (Gelbead) on concentration of Anti-Mullerian (AMH) hormone, fibroid volume and uterine artery patency. This prospective cohort study recruited consecutive patients from July 2017 to June 2018. Serum AMH, fibroid and uterine volume, UFS-QOL (uterine fibroid score-quality of life) scores were measured prior to and at 1 month and/or 3 months post embolization. Twenty-four participants were enrolled (median age 44 years, uterine volume 484 cm
3, initial dominant fibroid volume 167 cm
3). One patient was lost to follow-up. AMH (median ± SD) immediately prior to embolization was 3.2 ± 13.7 pmol/L. At 1-month postembolization, AMH was 4.1 ± 8.6 pmol/L and at 3 months 4.4 ± 8.6 pmol/L. We found no significant difference in AMH levels between baseline and at 1 month (p = 0.58) or baseline and 3 months (p = 0.17). The median dominant uterine fibroid volume decreased (167 to 64 cm
3, p < 0.001). At 3 months post-embolization, 17/23 patients had patent uterine arteries bilaterally (73.9%). UFE with Gel-bead did not significantly affect AMH at 3 months post embolization, whilst maintaining a high rate of uterine artery patency.
embolization, fertility, fibroid, resorbable, uterine
Hacking, Nigel
b6287f0b-1b80-49a6-a01a-f52f9da671c8
Vigneswaran, Ganesh
4e3865ad-1a15-4a27-b810-55348e7baceb
Maclean, Drew
9a01537b-1471-4ea2-9273-23f4a86157b0
Bryant, Timothy
b4eaf822-702a-40a6-990b-f178d751f7a9
Umranikar, Sameer
293e009a-22bd-4b62-8680-def7d7d361fb
Cheong, Ying
4efbba2a-3036-4dce-82f1-8b4017952c83
Modi, Sachin
1507f4a2-9733-4441-823a-666bb852e0f3
30 April 2021
Hacking, Nigel
b6287f0b-1b80-49a6-a01a-f52f9da671c8
Vigneswaran, Ganesh
4e3865ad-1a15-4a27-b810-55348e7baceb
Maclean, Drew
9a01537b-1471-4ea2-9273-23f4a86157b0
Bryant, Timothy
b4eaf822-702a-40a6-990b-f178d751f7a9
Umranikar, Sameer
293e009a-22bd-4b62-8680-def7d7d361fb
Cheong, Ying
4efbba2a-3036-4dce-82f1-8b4017952c83
Modi, Sachin
1507f4a2-9733-4441-823a-666bb852e0f3
Hacking, Nigel, Vigneswaran, Ganesh, Maclean, Drew, Bryant, Timothy, Umranikar, Sameer, Cheong, Ying and Modi, Sachin
(2021)
The Impact on Anti-Mullerian Hormone (AMH), uterine fibroid size and uterine artery patency following Uterine Fibroid Embolization (UFE) with a resorbable embolic agent.
Human Fertility.
(doi:10.1080/14647273.2021.1920055).
Abstract
The effect of Uterine Fibroid Embolization on fertility and ovarian reserve remains uncertain. We assessed the impact of a new resorbable, spherical particle (Gelbead) on concentration of Anti-Mullerian (AMH) hormone, fibroid volume and uterine artery patency. This prospective cohort study recruited consecutive patients from July 2017 to June 2018. Serum AMH, fibroid and uterine volume, UFS-QOL (uterine fibroid score-quality of life) scores were measured prior to and at 1 month and/or 3 months post embolization. Twenty-four participants were enrolled (median age 44 years, uterine volume 484 cm
3, initial dominant fibroid volume 167 cm
3). One patient was lost to follow-up. AMH (median ± SD) immediately prior to embolization was 3.2 ± 13.7 pmol/L. At 1-month postembolization, AMH was 4.1 ± 8.6 pmol/L and at 3 months 4.4 ± 8.6 pmol/L. We found no significant difference in AMH levels between baseline and at 1 month (p = 0.58) or baseline and 3 months (p = 0.17). The median dominant uterine fibroid volume decreased (167 to 64 cm
3, p < 0.001). At 3 months post-embolization, 17/23 patients had patent uterine arteries bilaterally (73.9%). UFE with Gel-bead did not significantly affect AMH at 3 months post embolization, whilst maintaining a high rate of uterine artery patency.
Text
Human_Fertility_AMH_revised
- Accepted Manuscript
Text
Human_Fertility_AMH_revised
Restricted to Repository staff only
Request a copy
More information
Accepted/In Press date: 28 February 2021
e-pub ahead of print date: 30 April 2021
Published date: 30 April 2021
Additional Information:
Funding Information:
This study was fully funded by a grant from Teleflex who produce Gelbead. Nigel Hacking has received honoraria from Boston Scientific and Celonova as a speaker and has been on Advisory boards for BTG. Tim Bryant has proctored for Boston Scientific and Terumo and has received speaker honorariums from Boston Scientific. Sachin Modi has received a speaker honorarium from Boston Scientific. The authors declare no conflict of interest.
Publisher Copyright:
© 2021 The British Fertility Society.
Keywords:
embolization, fertility, fibroid, resorbable, uterine
Identifiers
Local EPrints ID: 449359
URI: http://eprints.soton.ac.uk/id/eprint/449359
ISSN: 1464-7273
PURE UUID: 6c04ae8a-5dda-47f3-ba40-ccb4a2d5cdba
Catalogue record
Date deposited: 26 May 2021 16:30
Last modified: 17 Mar 2024 06:32
Export record
Altmetrics
Contributors
Author:
Nigel Hacking
Author:
Drew Maclean
Author:
Timothy Bryant
Author:
Sameer Umranikar
Author:
Sachin Modi
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
